GrayBug to Present at the 6th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research


January 9, 2014 – GrayBug is pleased to announce that it has been invited to present at the 6th Annual conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR) at the Beckman Center of the National Academies of Science and Engineering on January 23-25, 2014, in Irvine, CA.

About the BIMR

Through a generous grant from the Arnold and Mabel Beckman Foundation, the Beckman Initiative for Macular Research (BIMR) brings together outstanding scientists, engineers, medical researchers, and clinicians — all focused on a common goal: developing a better understanding of atrophic macular degeneration.

Related News

Press release

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

REDWOOD CITY, Calif., October 2, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Press release

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

Redwood City, CA – September 18, 2019 –Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Press release

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Redwood City, CA – August 20, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), Read more…